Diagnostic Performance of Magnetic Resonance Imaging for Assessing Tumor Response in Patients With HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy is Associated With Molecular Biomarker Profile

• Published in: Clinical breast cancer 2012-04, Vol.12 (2), p.110-118
• Main Authors: Kuzucan, Aida, Chen, Jeon-Hor, Bahri, Shadfar, Mehta, Rita S, Carpenter, Philip M, Fwu, Peter T, Yu, Hon J, Hsiang, David J.B, Lane, Karen T, Butler, John A, Feig, Stephen A, Su, Min-Ying
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - analysis; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Chemotherapy, Adjuvant; Female; Hematology, Oncology and Palliative Medicine; Hormone receptors; Humans; Immunohistochemistry; Ki-67; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant chemotherapy; Neoadjuvant Therapy; Obstetrics and Gynecology; Pathologic complete response; Receptor, ErbB-2 - biosynthesis; Receptors, Estrogen - biosynthesis; Receptors, Progesterone - biosynthesis; Sensitivity and Specificity; Triple-negative cancer
• ISSN: 1526-8209; 1938-0666
• DOI: 10.1016/j.clbc.2012.01.009

Micro-Abstract The influence of hormone receptors (HRs) and the Ki-67 proliferation marker in the accuracy of measuring tumor size by magnetic resonance imaging (MRI) after chemotherapy was investigated in 54 patients with HER2-negative (HER2− ) breast cancer. The accuracy was higher in HR-negative (HR− ) tumors than in HR-positive (HR+ ) tumors and was also higher in tumors with ≥ 40% Ki-67 staining than in those with < 40% Ki-67 staining, suggesting that the accuracy of MRI is better in more aggressive phenotypes.